On August 21, 2026, Werewolf Therapeutics entered into an Agreement and Plan of Merger with Ambros Therapeutics. Under the all-stock transaction, Ambros will merge into a wholly owned subsidiary of Werewolf, with pre-merger Ambros stockholders retaining approximately 71.7% ownership based on implied valuations of $500 million for Ambros and $47.5 million for Werewolf. Concurrently, Werewolf secured an oversubscribed private placement (PIPE) of $150 million to fund operations through the CRPS-RISE Phase 3 trial topline results in 2028 and planned NDA submission. The combined company will operate as Ambros Therapeutics under ticker AMBX on Nasdaq, focusing on neridronate for Complex Regional Pain Syndrome Type 1. Werewolf shareholders will retain approximately 6.8% ownership and receive contingent value rights related to legacy assets.

On August 14, 2026, Werewolf Therapeutics sold its pre-clinical INDUCER and INDUKINE platforms to EMD Serono Research & Development Institute Inc. for $33 million in upfront cash consideration. The company retains rights to develop WTX-124 and WTX-330 under an exclusive license from EMD. Werewolf Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

Werewolf Therapeutics reported second quarter 2026 financial results on July 31, 2026, driven by a $21.0 million asset sale of its JZP898 program to Jazz Pharmaceuticals. The transaction enabled the company to repay all amounts owed under its loan and security agreement with K2 HealthVentures LLC. Consequently, the company reported net income of $3.7 million compared to a net loss of $18.0 million in the prior year period. Cash and cash equivalents decreased to $22.0 million from $46.5 million at the end of the first quarter, with management projecting operations will be funded into the second quarter of 2027. The company is currently exploring strategic alternatives with financial advisor Piper Sandler & Co. Werewolf Therapeutics operates in the biopharmaceutical industry, developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.